DAXOR CORPORATION TO EXHIBIT AT THE MEDAXIOM CARDIOVASCULAR TRANSFORUM CONFERENCE SPRING’24 TO ADVANCE AWARENESS AND FURTHER ADOPTION OF DAXOR’S BLOOD VOLUME DIAGNOSTIC (BVA-100™)

Rhea-AI Summary

Daxor (Nasdaq: DXR) will exhibit at the MedAxiom CV Transforum Spring’24 Conference to showcase its blood volume diagnostic technology. The conference aims to transform cardiovascular care by providing education to industry leaders. Daxor's BVA diagnostic has shown significant improvements in patient outcomes, including mortality rates and readmissions, as well as reducing length of stay and healthcare costs.

Positive

• Daxor will showcase its blood volume diagnostic technology at the MedAxiom CV Transforum Spring’24 Conference.
• The conference focuses on transforming cardiovascular care and providing education to industry leaders.
• Daxor's BVA diagnostic has shown significant improvements in patient outcomes, including mortality rates and readmissions.
• BVA technology provides clinicians with accurate data to optimize treatment plans and individualize care, reducing healthcare costs.

Negative

• None.

The Premier Event for Cardiovascular Industry Leaders and Clinicians

Oak Ridge, TN, April 15, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today it will be exhibiting at the MedAxiom CV Transforum Spring’24 Conference being held at the Atlanta Marriott Marquis in GA, from April 18-20, 2024. The CV Transforum conference, hosted by MedAxiom, an American College of Cardiology company, unites cardiovascular thought leaders from across the country to transform cardiovascular care, featuring interactive industry-leading education designed for the MedAxiom membership community.

“MedAxiom’s spring conference provides an important opportunity to highlight our BVA diagnostic to cardiovascular leaders and innovators. Our aim is to demonstrate how our unique technology directly tackles issues such as readmissions, mortality, and resource optimization. These healthcare systems acknowledge MedAxiom as a leader in introducing solutions that improve outcomes, lower expenses, and enhance patient well-being,” said Michael Feldschuh, CEO and President of Daxor.

BVA-guided care has been shown in peer-reviewed studies to significantly improve multiple measures of patient outcomes including a reduction in 30-day mortality by 82%, 1-year mortality by 86%, 30-day readmissions by 56%, and results in a 57% reduction in length of stay when done on admission (P<0.001). BVA technology provides clinicians with 98% accurate, actionable data to optimize treatment plans and individualize care, improving outcomes while reducing duration and cost of care.

Register for the conference HERE.

View the Daxor Industry Partner Page.

About Daxor Corporation

Daxor Corporation (NASDAQ: DXR), is the global leader in blood volume measurement technology focused on blood volume testing innovation. We developed and market the BVA-100^® (Blood Volume Analyzer), the only diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000+ tests have been performed at leading hospital centers across the U.S., enhancing hospital performance metrics in a broad range of surgical and medical conditions, including significantly reducing mortality and readmissions in heart failure and critical care. Daxor has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the U.S. Department of Defense. Daxor's mission is to advance healthcare by enabling optimal fluid management with blood volume analysis. Daxor’s vision is optimal blood volume for all. For more information, please visit our website at Daxor.com. Sign up to receive news on Daxor’s innovative technology HERE.

Forward-Looking Statements

Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations Contact:

Bret Shapiro
Sr. Managing Partner, CORE IR
1-516-222-2560
brets@coreir.com

FAQ

What conference will Daxor exhibit at to showcase its blood volume diagnostic technology?

Daxor will exhibit at the MedAxiom CV Transforum Spring’24 Conference.

What improvements have been shown in patient outcomes using Daxor's BVA diagnostic?

Patient outcomes have shown improvements in mortality rates, readmissions, length of stay, and healthcare costs.

What percentage reduction in 30-day mortality has been achieved with BVA-guided care?

BVA-guided care has achieved an 82% reduction in 30-day mortality.

How accurate is the data provided by BVA technology to clinicians?

BVA technology provides clinicians with 98% accurate, actionable data.